Just saw that Dyne Therapeutics got orphan drug designation for Z-basivarsen in Japan for treating myotonic muscular dystrophy type 1. Pretty interesting because this compound already has orphan status from the FDA and EMA, plus Breakthrough Therapy and Fast Track designations. So now it's got global orphan recognition, which basically means accelerated development pathways across major markets. The Phase 1/2 ACHIEVE trial is ongoing. Not sure how many people this affects, but orphan drug programs usually move faster through regulatory channels. Worth keeping an eye on if you follow biotech advances.